logo
Mind, muscle, and metabolism: The power of holistic diabetes management

Mind, muscle, and metabolism: The power of holistic diabetes management

Time of India12 hours ago
When you think about diabetes, what's the first thing that comes to mind? Chances are, you thought of blood sugar levels. And yes, that's an important piece of the puzzle, but it's not the whole picture.
Living with diabetes is more than managing glucose. It's about caring for your whole self, mind, body, and lifestyle. And that's where a holistic approach comes in, one that doesn't just look at numbers on a glucometer but considers your food, movement, emotions, sleep, and even stress.
So, let's discuss what a 360-degree diabetes care plan looks like and how it can help you feel more in control, energised, and hopeful.
ET Spotlight
Dr Mala Dharmalingam | Sr. Consultant Endocrinologist. Bangalore endocrinology and diabetes center, Malleswaram
The power of lifestyle
Did you know that lifestyle plays such an important role in managing diabetes? It's not just about taking medication or steering clear of sugar; it's about embracing how you live your daily life.
While being disciplined about food is essential, that doesn't mean that eating has to feel dull or limited. In fact, making small changes like adding a bit more fibre to your meals, reducing those ultra-processed snacks, or enjoying your veggies first, can boost your blood sugar response and help you feel satisfied for a long time!
1-3
Live Events
Exercise, too, doesn't necessarily have to be complex. Just taking a pleasant 30-minute walk most days can boost your insulin sensitivity, aid in weight management, and brighten your mood. And let's not forget about strength training, it keeps those muscles strong, which is so important since strong muscles help your body use sugar more efficiently.
4,5
Your mind matters too
Here's something we really should discuss more: your mental and emotional health. Living with a chronic condition can often feel overwhelming, and it's completely normal to experience stress, worry, and even guilt or burnout.
But be aware that these emotional ups and downs can influence your blood sugar levels, too! Stress hormones such as cortisol might raise your blood sugar, while poor sleep or anxiety can complicate diabetes management.
6-8
That's why taking care of your mental wellness isn't just an added benefit in diabetes care; it's an essential part of your plan. Therefore, if you're feeling anxious or unsure, don't hesitate to talk to someone! Reach out to a friend, a counsellor, or a diabetes educator. Remember, you're not alone on this journey, and having support can truly make a world of difference.
ET Spotlight
Hormones you should know: GLP-1 and insulin
Here's a fun fact: Your body produces a hormone called GLP-1 after you eat. This little helper plays a big role in controlling your blood sugar, slowing down digestion, and signalling your brain, 'Hey, I'm full.' Isn't that clever?
9-11
This hormone doesn't always do its job well in people with diabetes. That's why researchers have been exploring ways to work with GLP-1 to manage diabetes better. The more we understand how our body naturally works, the better we can support it through lifestyle, diet, and, when needed, the right medical care.
However, GLP-1 doesn't work alone. Another key player is insulin, a hormone made by your pancreas. Insulin helps move sugar from your blood into your cells, where it's used for energy. After a meal, insulin levels rise to keep your blood sugar in check.
In people with diabetes, these hormones don't always do their jobs well. That's why researchers have been exploring ways to work with GLP-1 and insulin to manage diabetes better. The more we understand how our body naturally works, the better we can support it through lifestyle, diet, and, when needed, the right medical care.
The bottom line: Think bigger, feel better
Managing diabetes involves much more than just one part of your body; it's a beautiful dance of all the systems working together! By nurturing your mind, caring for your muscles, making balanced meal choices, and keeping a positive mood, you create a strong foundation for lasting health and well-being.
Why not consider doing a few simple things today to boost your well-being? You could take a lovely short walk after lunch, try out a delicious new veggie-based recipe, or take a moment to check in with how you're feeling. And if you have a chance, chatting with your doctor can be really helpful to learn about a personalised treatment plan and your entire health journey!
Remember, our body is wonderfully connected; diabetes care is not about perfection but progress and being consistent by making wiser choices.
ET Spotlight
Key takeaways:
Diabetes care encompasses more than sugar control; it's about your entire lifestyle: food, movement, sleep, stress, and mindset.
Small changes, such as daily walking, increasing fibre, and reducing processed foods, create significant impacts.
Your mental health matters: stress, sleep, and emotions impact blood sugar. Don't ignore them.
Your body has an intelligent helper called GLP-1; understanding how it functions can enhance diabetes management through both lifestyle adjustments and medical care.
References:
Flores-Hernández MN, Martínez-Coria H, López-Valdés HE, et al. Efficacy of a High-Protein Diet to Lower Glycemic Levels in Type 2 Diabetes Mellitus: A Systematic Review. International Journal of Molecular Sciences. 2024;25(20):10959.
Forouhi NG, Misra A, Mohan V, Taylor R, Yancy W. Dietary and nutritional approaches for prevention and management of type 2 diabetes. BMJ. 2018;361:k2234.
Dazıroğlu ME, Tek NA. Water Consumption: Effect on Energy Expenditure and Body Weight Management. Current Obesity Reports. 2023;12:99-107.
30-Minute Daily Walk Helps Prevent Diabetes and Age-Related Diseases.
Diabetes.co.uk.
Available from:
Link
. Accessed on 2 July 2025.
Ambelu T, Teferi G. The impact of exercise modalities on blood glucose, blood pressure, and body composition in patients with type 2 diabetes mellitus. BMC Sports Science, Medicine and Rehabilitation. 2023;15:153.
Tellhed U, Daukantaitė D, Maddux RE, et al. Yogic breathing and mindfulness as stress coping mediate positive health outcomes of yoga. Mindfulness. 2019;10:2703–2715.
Tibor liu. The stress hormone: How cortisol affects diabetes outcomes and its managing and monitoring. Diabetes Manag. 2024;14(5):663–664.
H. Klar Yaggi, Andre B. Araujo, John B. McKinlay; Sleep Duration as a Risk Factor for the Development of Type 2 Diabetes.
Diabetes Care
. March 2006;29(3):657–661.
Zhang, X., Cao, C., Zheng, F.
et al.
Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications. Cardiovasc Drugs Ther.2025.
Huber, Hanna et al. Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions–a narrative review. The American Journal of Clinical Nutrition;119;3:599– 627.
van Bloemendaal L, IJzerman RG, ten Kulve JS, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63(12):4186–4196.
This content is part of a disease awareness initiative by Novo Nordisk. The opinions and views are that of the Healthcare Professionals. The news and editorial staff of ET had no role in the creation of this article nor vouch for or endorse any of its content. While the content on this site provides general information about health and wellbeing. It is not intended as medical advice, nor is it a substitute for professional medical expertise or treatment. If you need help getting your health under control, we recommend speaking to your doctor.
Economic Times WhatsApp channel
)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?

Economic Times

time2 hours ago

  • Economic Times

Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?

Hims & Hers Health (NYSE: HIMS) saw its stock plunge over 11% after the company reported its Q2 2025 earnings, marking its first-ever sequential revenue decline. While revenue jumped 73% year-over-year to $544.8 million, it still fell short of Wall Street's expectations of $552 million, and notably dropped from $586 million in Q1. The miss has rattled investor confidence, especially as GLP-1 weight-loss drug sales, a key growth driver, showed signs of slowing amid regulatory pressure and legal setbacks. Synopsis Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming weight-loss drug business. While year-over-year sales jumped 73%, revenue fell sequentially for the first time, causing investor worry. The company brought in $544.8 million, short of forecasts, with much of it tied to its GLP-1 obesity drug offerings. Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever sequential revenue decline, raising questions about the future of its GLP-1 obesity drug business. ADVERTISEMENT Despite its rapid annual growth, Hims & Hers posted Q2 revenue of $544.8 million, missing the analyst estimate of $552 million. The real concern? Revenue dropped from $586 million in Q1, marking the first quarter-over-quarter decline since the company went public. The stock currently trades at $63.35, regaining some ground after hitting an intraday low of $54.82. Despite opening at $64.00, it remains volatile, with an intraday high of $65.54. ALSO READ: Bullish IPO debut: Peter Thiel-backed crypto giant targets $4.2B valuation—is the new crypto wave knocking on Wall Street's door? The market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business segment. ALSO READ: Palantir stock soars after $1B Q2 earnings crush forecasts as AI demand fuels 110% YTD surge—now S&P 500's top performer ADVERTISEMENT With regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and Europe. Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Investors were caught off guard, as the slowdown came amid soaring demand for weight-loss drugs like semaglutide, a compound similar to the active ingredient in Wegovy and Ozempic. ADVERTISEMENT On the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings win. Investors appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent growth. ADVERTISEMENT Hims' biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged: Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA. ADVERTISEMENT A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic uncertainty. One bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental wellness. CEO Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product categories. If you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor: Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply uncertainty. For now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care ecosystem. What caused Hims & Hers stock to fall 11% after Q2 earnings? The company missed revenue estimates and saw its first-ever sequential drop in sales. Is the Hims weight-loss drug business facing trouble in 2025? Yes, due to FDA scrutiny and legal issues around compounded semaglutide. (You can now subscribe to our Economic Times WhatsApp channel) (Catch all the US News, UK News, Canada News, International Breaking News Events, and Latest News Updates on The Economic Times.) Download The Economic Times News App to get Daily International News Updates. NEXT STORY

Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?

Time of India

time5 hours ago

  • Time of India

Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?

Why did Hims & Hers stock fall after earnings? Live Events Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Earnings beat estimates, but Wall Street stays cautious Is the GLP‑1 weight-loss business at risk? Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Hims keeps full-year guidance intact—thanks to international expansion Subscriber growth remains strong despite volatility What investors should watch going forward Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims still growing, but cracks are showing FAQs: (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever, raising questions about the future of itsDespite its rapid annual growth, Hims & Hers posted, missing the analyst estimate of. The real concern? Revenue dropped from, marking the first quarter-over-quarter decline since the company went stock currently trades at, regaining some ground after hitting an intraday low of. Despite opening at, it remains volatile, with an intraday high ofThe market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and were caught off guard, as the slowdown came amid soaring demand forlike semaglutide, a compound similar to the active ingredient in Wegovy and the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged:Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA.A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor:Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care company missed revenue estimates and saw its first-ever sequential drop in due to FDA scrutiny and legal issues around compounded semaglutide.

4 days of survey detects mosquito larvae in nearly 8,000 Nagpur homes
4 days of survey detects mosquito larvae in nearly 8,000 Nagpur homes

Time of India

time5 hours ago

  • Time of India

4 days of survey detects mosquito larvae in nearly 8,000 Nagpur homes

1 2 Nagpur: A whopping 1,46,509 houses were surveyed across Nagpur in just four days as part of the Nagpur Municipal Corporation (NMC) civic body's intensified campaign to detect mosquito breeding sites. This translates to an average of 36,627 houses inspected each day by a combined workforce of 1,183 personnel — comprising 1,088 Asha workers and 95 mosquito breeding checkers — working in 8-hour shifts. On average, each staffer covered approximately 31 houses per day, reflecting the sheer scale and speed of the door-to-door survey launched by the NMC from August 1. The drive, aimed at curbing the spread of dengue, malaria, and chikungunya, found mosquito larvae in 7,986 homes during the initial days of the survey. A total of 1,088 Asha workers were deployed across the city's 10 zones, with each worker assigned specific localities. Asha workers conducted house-to-house visits to detect mosquito breeding sites such as water coolers, flowerpots, utensils, drums, and discarded containers. Stagnant water in these objects can become breeding grounds for mosquitoes within a week, increasing the risk of disease outbreaks. The survey work was supported by NMC's 95 mosquito breeding checkers, who also visited households to detect and destroy larvae. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like These Countries Are Known for Being the Least Friendly BigGlobalTravel Undo Apart from conducting regular fogging and spraying, NMC is also running public awareness campaigns to encourage preventive measures. While the mosquito breeding checkers covered 20,876 houses and found larvae in 853, Asha workers surveyed 1,25,633 homes and detected larvae in 7,133 — revealing the scale of mosquito breeding hotspots across the city. Together, they also inspected 76,680 containers such as water coolers, drums, buckets, and flowerpots, of which 2,575 were found to be contaminated with larvae. So far, nine cases of dengue and three of chikungunya have been confirmed in the city since July 1. Under the supervision of additional commissioner Vasumana Pant and medical officer Dr Deepak Selokar, the civic body has intensified fogging, spraying, and larvicide application in vulnerable areas, including slums and vacant plots. Mosquito samples are also being tested to identify the diseases they may transmit. Dr Selokar urged citizens to cooperate with NMC teams and ensure no water is left stagnant around homes. "Public participation is crucial in preventing outbreaks. Every household must stay vigilant," he said. INFOBOX-1 Survey and Larvae Detection Data (Aug 1–4, 2025): Mosquito Breeding Checkers: Surveyed 20,876 homes; larvae found in 853 homes Asha Workers: Surveyed 125,633 homes; larvae found in 7,133 homes Total Homes Surveyed: 146,509 Total Homes with Larvae: 7,986 INFOBOX-2 Container Inspections (Potential Mosquito Breeding Sources) By Mosquito Breeding Checkers: 26,992 containers inspected; 415 found contaminated By Asha Workers: 49,688 containers inspected; 2,160 found contaminated

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store